Shares of Zafgen Inc (NASDAQ:ZFGN) have received an average recommendation of “Hold” from the ten ratings firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $7.42.
A number of research firms have recently issued reports on ZFGN. Zacks Investment Research upgraded shares of Zafgen from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a report on Saturday, May 18th. Wedbush reiterated a “buy” rating and issued a $6.00 price objective on shares of Zafgen in a report on Thursday, May 16th. ValuEngine downgraded shares of Zafgen from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Svb Leerink upgraded shares of Zafgen from a “market perform” rating to an “outperform” rating in a report on Thursday, February 7th. Finally, Roth Capital began coverage on shares of Zafgen in a report on Friday, April 26th. They issued a “buy” rating and a $8.00 price objective on the stock.
ZFGN traded up $0.03 during trading on Friday, reaching $2.67. The company had a trading volume of 37 shares, compared to its average volume of 264,667. The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.83 and a current ratio of 7.83. Zafgen has a 12 month low of $2.33 and a 12 month high of $12.35. The firm has a market cap of $97.05 million, a P/E ratio of -1.41 and a beta of -0.45.
Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.40) by $0.05. On average, sell-side analysts anticipate that Zafgen will post -1.39 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the stock. First Manhattan Co. acquired a new position in shares of Zafgen in the fourth quarter valued at $27,000. SG Americas Securities LLC bought a new stake in shares of Zafgen in the first quarter valued at about $43,000. Meeder Asset Management Inc. boosted its position in shares of Zafgen by 547.1% in the fourth quarter. Meeder Asset Management Inc. now owns 9,118 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 7,709 shares during the period. Prudential Financial Inc. bought a new stake in shares of Zafgen in the fourth quarter valued at about $65,000. Finally, Alambic Investment Management L.P. bought a new stake in shares of Zafgen in the first quarter valued at about $95,000. Institutional investors and hedge funds own 84.36% of the company’s stock.
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Further Reading: What are the FAANG Stocks?
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.